Novartis Ag

University of Pennsylvania

Brian Walter Granda

Jennifer Brogdon

Boris Engels

Lu Huang

Ming Lei

Carla Guimaraes

Jimin Zhang

Na Li

Andreas Loew

Saar Gill

Barbara Brannetti

Marco Ruella

Connie Hong

Regina M Young

Michael C Milone

David Jonathan Glass

Qilong Wu

Joan Mannick

Brian Edward Vash

Leon Murphy

Jan Weiler

Huijuan Song

Li Zhou

William Raj Sellers

John Hastewell

Dattananda Chelur

Glenn Dranoff

Chonghui Zhang

Tony Fleming

Aida Abujoub

John Blankenship

Brian Holmberg

Regis Cebe

Dexiu Bu

Haihui Lu

Michael R Greene

Xu Zhu

Carla Patricia Pinto Guimaraes

Melissa Ramones

Amy Rayo

Andrew Marc Stein

Akash Sohoni

Attilio Bondanza

Olja Kodrasi

Elizabeth Dorothy Pratico

Hyungwook Lim

Serena De Vita

Anniesha Hack

Joni Waiee Lam

Sunyoung Jang

Andrew Price

Louise Treanor

Yingqi Karen Wang

Daniel B Wall

The invention provides immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions and methods thereof.

Chimeric antigen receptors and uses thereof

The present disclosure provides CD19 binding molecules that specifically bind to CD19, including monospecific, bispecific and trispecific binding molecules, conjugates comprising the CD19 binding molecules, and pharmaceutical compositions comprising the CD19 binding molecules and the conjugates. The disclosure further provides methods of using the C19 binding molecules to treat diseases and disorders associated with expression of CD19. The disclosure yet further provides recombinant host cells engineered to express the CD19 binding molecules and methods of producing the CD19 binding molecules by culturing the host cells under conditions in which the CD19 binding molecules are expressed.

CD19 binding molecules and uses thereof

The present disclosure provides CD2 binding molecules that specifically bind to CD2, including monospecific, bispecific and trispecific binding molecules, conjugates comprising the CD2 binding molecules, and pharmaceutical compositions comprising the CD2 binding molecules and the conjugates. The disclosure further provides methods of using the CD2 binding molecules to modulate CD2 signaling in order to treat a variety of immune (e.g., autoimmune), inflammatory and proliferative disorders. The disclosure yet further provides recombinant host cells engineered to express the CD2 binding molecules and methods of producing the CD2 binding molecules by culturing the host cells under conditions in which the CD2 binding molecules are expressed.

Variant CD58 domains and uses thereof

The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.

Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain

Method of treating cancer by administering immune effector cells expressing a chimeric antigen receptor comprising a CD20 binding domain

The present disclosure features the use of chimeric CD3 proteins to modulate T cell Receptor (TCR) signaling. Specifically, the disclosure is based, in part, on the discovery that chimeric CD3 proteins (e.g., CD3delta, CD3gamma, and CD3epsilon) having all or most of their extracellular domain fused to an antigen binding domain can activate the TCR in the presence of a cognate antigen. The disclosure is further based on the observation that the above chimeric proteins can be potentiated through the inclusion of a co-stimulatory domain in the intracellular portion of the chimeric molecule. Thus, the preferred elements of the engineered signaling complexes of the disclosure include an antigen binding domain, an extracellular domain derived from one of the above CD3 proteins, and an intracellular co-stimulatory domain.

Treatment of cancer using chimeric CD3 receptor proteins

Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.

Regulatable chimeric antigen receptor

Growing community of inventors

Salisbury, MA, United States of America

Brian Walter Granda